Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
No open-market purchases versus $70.4K in reported salesOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hastings Paul J | Chief Executive Officer | Jun 18 '26 | Sale | $2.71 | 1,776 | $4,813 | 390,247 | Jun 22 04:05 PM |
| Hastings Paul J | Chief Executive Officer | Jan 15 '26 | Sale | $2.07 | 26,046 | $53,915 | 390,023 | Jan 20 05:39 PM |
| Mahmood Nadir | President | Jan 15 '26 |
Company profile
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| $2.07 |
| 5,649 |
| $11,693 |
| 167,727 |
| Jan 20 05:38 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.